Mark Hannon serves as the Vice President of Operations at Prolacta Bioscience, where he leverages his extensive expertise in Lean Manufacturing and operational excellence to drive transformative initiatives that align with the company’s mission of enhancing the lives of vulnerable infants. With a robust background...
Mark Hannon serves as the Vice President of Operations at Prolacta Bioscience, where he leverages his extensive expertise in Lean Manufacturing and operational excellence to drive transformative initiatives that align with the company’s mission of enhancing the lives of vulnerable infants. With a robust background in the pharmaceutical industry, Mark is adept at navigating the complexities of regulatory compliance, particularly in relation to FDA standards and Good Manufacturing Practices (GMP). His strategic vision is complemented by a hands-on approach to process improvement, utilizing methodologies such as DMAIC to streamline operations and enhance product quality.
At Prolacta, Mark is currently spearheading key projects aimed at optimizing the organizational structure and operational workflows. His leadership in developing tactical plans has not only improved efficiency but has also ensured that the company meets its aggressive financial and operational objectives. By fostering a culture of continuous improvement and innovation, he has successfully implemented corrective and preventive actions (CAPA) that address critical challenges in the manufacturing process, thereby enhancing the overall quality of Prolacta's life-saving products.
Mark’s commitment to operational excellence is evident in his ability to transform complex problems into simple, actionable solutions. His expertise in verification and validation (V&V) processes ensures that Prolacta’s products not only meet but exceed industry standards, ultimately contributing to the company’s goal of delivering world-class research and innovative solutions for the most fragile infants. Through his leadership, Prolacta Bioscience continues to make a meaningful difference in neonatal care, reinforcing its position as a leader in the life sciences sector.
